

TABLE 4—MAIN CLINICAL AND LABORATORY FINDINGS (% or median and range) IN 186 CASES OF AvWS

<i>Associated disorders:</i>	<i>Lymphoproliferative</i>	<i>Myeloproliferative</i>	<i>Neoplasia</i>	<i>Immunologic</i>	<i>Cardiovascular</i>	<i>Miscellaneous</i>	<i>TOTAL</i>
Case number (%):	89 (48)	29 (15)	9 (5)	4 (2)	39 (21)	16 (9)	186 (100)
Sex (% of male)	63	35	45	20	57	36	<u>53</u>
Age at onset (years)	64 (28-96)	45 (27-72)	62 (26-93)	52 (40-58)	68 (2-85)	44 (6-75)	<u>62</u> (2-96)
Still alive (%)	55	24	67	80	57	73	<u>53</u>
Bleeders (%)	87	48	75	60	77	57	<u>72</u>
Bleeding time (min)	15 (3->30)	11 (3-22)	20 (5-20)	5 (3-8)	14 (5->30)	20 (10->30)	<u>15</u> (3->30)
APTT (patient / normal ratio)	1.4 (1-2.5)	1.0 (1-1.37)	1.0 (0.9-1.7)	1.20 (0.86-1.89)	1.37 (1.2-1.7)	1.2 (1.2-1.7)	<u>1.30</u> (0.9-2.5)
FVIII:C (U/dL,mean)	20 (4-92)	45 (16-75)	23 (12-83)	112 (33-191)	28 (3-185)	33 (3-191)	<u>25</u> (3-191)
VWF:Ag (U/dL,)	17 (4-80)	70 (20-404)	20 (5-59)	39 (14-91)	113 (8-300)	94 (10-221)	<u>33</u> (4-404)
VWF:RCo or VWF:CB (U/dL)	8 (3-45)	39 (3-130)	10 (4-32)	26 (10-40)	60 (3-150)	6 (6-144)	<u>20</u> (3-150)
VWF:RCo or VWF:CB/Ag (ratio)	0.57 (0.08-1.50)	0.52 (0.11-1.40)	0.69 (0.10-1.50)	0.53 (0.23-1.22)	0.47 (0.13-1.57)	0.58 (0.31-1.23)	<u>0.50</u> (0.08-1.50)
VWF:AgII	75 (60-121)	n.t.	n.t.	n.t.	n.t.	n.t.	<u>n.c.</u>
Plasma Multimers: lack of H.M.W. multimers (%)	76	86	96	80	80	70	<u>83</u>
positive anti-FVIII/VWF (%)	12	0	22	42	0	9	<u>7</u>

n.t. = not tested; n.c. = not calculated;